Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis

 

 Permissions and Reprints

Abstract

von Willebrand factor (VWF) is a large adhesive multimeric protein involved in hemostasis. The larger the size (or number of VWF multimers), the greater the functionality of the protein. A deficiency or defect of VWF can lead to von Willebrand disease (VWD) and cause bleeding. Conversely, an increase in VWF may create an environment that promotes thrombosis. ADAMS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), sometimes called VWF-cleaving protease, is primarily responsible for controlling the size of VWF. The most severe deficiency (<10% of normal levels) of ADAMTS-13 arises in thrombotic thrombocytopenic purpura, a condition characterized by the presence of ultralarge VWF and clinically resulting in enhanced risk of thrombosis. However, ADAMTS-13 deficiency may result from other pathological processes. Of relevance is the recent finding that COVID-19 (coronavirus disease 2019) is associated with both increased levels and activity of VWF as well as generally decreased (or occasionally normal) activity levels of ADAMTS-13. Thus, in COVID-19 there is an alteration in the VWF/ADAMTS-13 axis, most often described by increased VWF/ADAMTS-13 ratio (or reduced ADAMTS-13/VWF ratio). COVID-19 is also associated with high prothrombotic risk. Thus, the imbalance of VWF and ADAMTS-13 in COVID-19 may be providing a milieu that promotes (micro)thrombosis, in a clinical picture resembling a secondary thrombotic microangiopathy in some patients. This review therefore assesses the literature on VWF, ADAMTS-13, and COVID-19. Whenever reported in COVID-19, VWF has always been identified as raised (compared with normal reference ranges or control populations). Reports have included VWF level (i.e., VWF antigen) and in some cases one or more VWF “activity” (e.g., collagen binding; platelet glycoprotein Ib [GPIb] binding, using ristocetin cofactor or more modern versions including VWF:GPIbR [recombinant] and VWF:GPIbM [mutant]). Whenever reported, ADAMTS-13 has been reported as “normal” or reduced; however, it should be recognized that “normal” levels may still identify a relative reduction in individual cases. Some reports also discuss the raised VWF/ADAMTS-13 (or reduced ADAMTS-13/VWF) ratio, but very few provide actual numerical data.

Publication History

Article published online:
23 April 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Yee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Hemost 2014; 40 (01) 17-27
  PubMedGoogle Scholar
• 2 Favaloro EJ, Pasalic L, Curnow J. Monitoring therapy during treatment of von Willebrand disease. Semin Thromb Hemost 2017; 43 (03) 338-354
  PubMedGoogle Scholar
• 3 Calabrò P, Gragnano F, Golia E, Grove EL. von Willebrand factor and venous thromboembolism: pathogenic link and therapeutic implications. Semin Thromb Hemost 2018; 44 (03) 249-260
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Blennerhassett R, Curnow J, Pasalic L. Immune-mediated thrombotic thrombocytopenic purpura: a narrative review of diagnosis and treatment in adults. Semin Thromb Hemost 2020; 46 (03) 289-301
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J 2019; 12 (03) 333-337
  CrossrefPubMedGoogle Scholar
• 6 Favaloro EJ, Henry BH, Lippi G. VWF and ADAMTS13 in COVID-19 and beyond: a question of balance. 2021 ; in press
  PubMedGoogle Scholar
• 7 Panigada M, Bottino N, Tagliabue P. et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18 (07) 1738-1742
  CrossrefPubMedGoogle Scholar
• 8 Poissy J, Goutay J, Caplan M. et al; Lille ICU Haemostasis COVID-19 Group. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 2020; 142 (02) 184-186
  CrossrefPubMedGoogle Scholar
• 9 Helms J, Tacquard C, Severac F. et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46 (06) 1089-1098
  CrossrefPubMedGoogle Scholar
• 10 Goshua G, Pine AB, Meizlish ML. et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 2020; 7 (08) e575-e582
  CrossrefPubMedGoogle Scholar
• 11 Ladikou EE, Sivaloganathan H, Milne KM. et al. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19?. Clin Med (Lond) 2020; 20 (05) e178-e182
  CrossrefPubMedGoogle Scholar
• 12 Masi P, Hékimian G, Lejeune M. et al. Systemic inflammatory response syndrome is a major contributor to COVID-19-associated coagulopathy: insights from a prospective, single-center cohort study. Circulation 2020; 142 (06) 611-614
  CrossrefPubMedGoogle Scholar
• 13 Sardu C, Marfella R, Maggi P. et al. Implications of ABO blood group in hypertensive patients with covid-19. BMC Cardiovasc Disord 2020; 20 (01) 373
  CrossrefPubMedGoogle Scholar
• 14 Rauch A, Labreuche J, Lassalle F. et al. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19. J Thromb Haemost 2020; 18 (11) 2942-2953
  CrossrefPubMedGoogle Scholar
• 15 Hoechter DJ, Becker-Pennrich A, Langrehr J. et al. Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patients compared to non-COVID-19 ARDS patients. Thromb Res 2020; 196: 186-192
  CrossrefPubMedGoogle Scholar
• 16 Taus F, Salvagno G, Canè S. et al. platelets promote thromboinflammation in SARS-CoV-2 pneumonia. Arterioscler Thromb Vasc Biol 2020; 40 (12) 2975-2989
  CrossrefPubMedGoogle Scholar
• 17 Fan BE, Ng J, Chan SSW. et al. COVID-19 associated coagulopathy in critically ill patients: a hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis. J Thromb Thrombolysis 2021; 51 (03) 663-674
  CrossrefPubMedGoogle Scholar
• 18 Cugno M, Meroni PL, Gualtierotti R. et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. J Autoimmun 2021; 116: 102560
  CrossrefPubMedGoogle Scholar
• 19 Ward SE, Curley GF, Lavin M. et al; Irish COVID-19 Vasculopathy Study (ICVS) Investigators. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. Br J Haematol 2021; 192 (04) 714-719
  CrossrefPubMedGoogle Scholar
• 20 Ruberto F, Chistolini A, Curreli M. et al; Policlinico Umberto I COVID-19 Group. Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?. J Thromb Thrombolysis 2021; (epub ahead of print) DOI: 10.1007/s11239-020-02339-6.
  CrossrefPubMedGoogle Scholar
• 21 Heinz C, Miesbach W, Herrmann E. et al. Greater fibrinolysis resistance but no greater platelet aggregation in critically ill COVID-19 patients. Anesthesiology 2021; 134 (03) 457-467
  CrossrefPubMedGoogle Scholar
• 22 Philippe A, Chocron R, Gendron N. et al. Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis 2021; (epub ahead of print) DOI: 10.1007/s10456-020-09762-6.
  CrossrefPubMedGoogle Scholar
• 23 Vassiliou AG, Keskinidou C, Jahaj E. et al. ICU admission levels of endothelial biomarkers as predictors of mortality in critically ill COVID-19 patients. Cells 2021; 10 (01) 186
  CrossrefPubMedGoogle Scholar
• 24 Bauer W, Galtung N, Neuwinger N. et al. A matter of caution: coagulation parameters in COVID-19 do not differ from patients with ruled-out SARS-CoV-2 infection in the emergency department. TH Open 2021; 5 (01) e43-e55
  Article in Thieme ConnectPubMedGoogle Scholar
• 25 Martinelli N, Montagnana M, Pizzolo F. et al. A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19. Thromb Res 2020; 193: 170-172
  CrossrefPubMedGoogle Scholar
• 26 Rovas A, Osiaevi I, Buscher K. et al. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis 2021; 24 (01) 145-157
  CrossrefPubMedGoogle Scholar
• 27 Alharthy A, Faqihi F, Balhamar A, Memish ZA, Karakitsos D. Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: a case series. SAGE Open Med Case Rep 2020; (epub ahead of print) DOI: 10.1177/2050313X20964089.
  CrossrefPubMedGoogle Scholar
• 28 Huisman A, Beun R, Sikma M, Westerink J, Kusadasi N. Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2. Int J Lab Hematol 2020; 42 (05) e211-e212
  CrossrefPubMedGoogle Scholar
• 29 Bazzan M, Montaruli B, Sciascia S, Cosseddu D, Norbiato C, Roccatello D. Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Intern Emerg Med 2020; 15 (05) 861-863
  CrossrefPubMedGoogle Scholar
• 30 Morici N, Bottiroli M, Fumagalli R, Marini C, Cattaneo M. Role of von Willebrand factor and ADAMTS-13 in the pathogenesis of thrombi in SARS-CoV-2 infection: time to rethink. Thromb Haemost 2020; 120 (09) 1339-1342
  Article in Thieme ConnectPubMedGoogle Scholar
• 31 Blasi A, von Meijenfeldt FA, Adelmeijer J. et al. In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. J Thromb Haemost 2020; 18 (10) 2646-2653
  CrossrefPubMedGoogle Scholar
• 32 Tiscia GL, Favuzzi G, De Laurenzo A. et al; CSS COVID-19 Group. Reduction of ADAMTS13 levels predicts mortality in SARS-CoV-2 patients. TH Open 2020; 4 (03) e203-e206
  Article in Thieme ConnectPubMedGoogle Scholar
• 33 Fraser DD, Patterson EK, Slessarev M. et al. Endothelial injury and glycocalyx degradation in critically ill coronavirus disease 2019 patients: implications for microvascular platelet aggregation. Crit Care Explor 2020; 2 (09) e0194
  CrossrefPubMedGoogle Scholar
• 34 Sweeney JM, Barouqa M, Krause GJ, Gonzalez-Lugo JD, Rahman S, Gil MR. Evidence for secondary thrombotic microangiopathy in COVID-19. medRxiv 2020; (epub ahead of print) DOI: 10.1101/2020.10.20.20215608.
  CrossrefPubMedGoogle Scholar
• 35 Hardy M, Michaux I, Lessire S. et al. Prothrombotic hemostasis disturbances in patients with severe COVID-19: individual daily data. Data Brief 2020; 33: 106519
  CrossrefPubMedGoogle Scholar
• 36 Mancini I, Baronciani L, Artoni A. et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost 2021; 19 (02) 513-521
  CrossrefPubMedGoogle Scholar
• 37 Henry BM, Benoit SW, de Oliveira MHS, Lippi G, Favaloro EJ, Benoit JL. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy. Int J Lab Hematol 2020; (epub ahead of print) DOI: 10.1111/ijlh.13415.
  CrossrefPubMedGoogle Scholar
• 38 Arulkumaran N, Thomas M, Brealey D. et al. Plasma exchange for COVID-19 thrombo-inflammatory disease. EJHaem 2020; (epub ahead of print) DOI: 10.1002/jha2.140.
  CrossrefPubMedGoogle Scholar
• 39 Delrue M, Siguret V, Neuwirth M. et al. von Willebrand factor/ADAMTS13 axis and venous thromboembolism in moderate-to-severe COVID-19 patients. Br J Haematol 2021; 192 (06) 1097-1100
  CrossrefPubMedGoogle Scholar
• 40 Fernández-Pérez MP, Águila S, Reguilón-Gallego L. et al. Neutrophil extracellular traps and von Willebrand factor are allies that negatively influence COVID-19 outcomes. Clin Transl Med 2021; 11 (01) e268
  CrossrefPubMedGoogle Scholar
• 41 Rodríguez Rodríguez M, Castro Quismondo N, Zafra Torres D, Gil Alos D, Ayala R, Martinez-Lopez J. Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients. Int J Lab Hematol 2021; (ePub ahead of print) DOI: 10.1111/ijlh.13476.
  CrossrefPubMedGoogle Scholar
• 42 De Jongh R, Ninivaggi M, Mesotten D. et al. Vascular activation is a strong predictor of mortality in coronavirus disease 2019 patients on the ICU. Blood Coagul Fibrinolysis 2021; (epub ahead of print) DOI: 10.1097/MBC.0000000000001007.
  CrossrefPubMedGoogle Scholar
• 43 De Cristofaro R, Liuzzo G, Sacco M, Lancellotti S, Pedicino D, Andreotti F. Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study. Blood Coagul Fibrinolysis 2021; (epub ahead of print) DOI: 10.1097/MBC.0000000000000998.
  CrossrefPubMedGoogle Scholar
• 44 von Meijenfeldt FA, Havervall S, Adelmeijer J. et al. Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality. Res Pract Thromb Haemost 2020; 5 (01) 132-141
  CrossrefPubMedGoogle Scholar
• 45 Falter T, Rossmann H, Menge P. et al. No evidence for classic thrombotic microangiopathy in COVID-19. J Clin Med 2021; 10 (04) 671
  CrossrefPubMedGoogle Scholar
• 46 Pascreau T, Zia-Chahabi S, Zuber B, Tcherakian C, Farfour E, Vasse M. ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19. Thromb Res 2021; (epub ahead of print) DOI: 10.1016/j.thromres.2021.02.008.
  CrossrefPubMedGoogle Scholar
• 47 Doevelaar AAN, Bachmann M, Hölzer B. et al. von Willebrand factor multimer formation contributes to immunothrombosis in coronavirus disease 2019. Crit Care Med 2021; 49 (05) e512-e520
  CrossrefPubMedGoogle Scholar
• 48 Favaloro EJ. Navigating the myriad of von Willebrand factor assays. Hamostaseologie 2020; 40 (04) 431-442
  Article in Thieme ConnectPubMedGoogle Scholar
• 49 Favaloro EJ, Mohammed S. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Thromb Res 2016; 141: 202-211
  CrossrefPubMedGoogle Scholar
• 50 Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010; 104 (05) 1009-1021
  Article in Thieme ConnectPubMedGoogle Scholar
• 51 Oliver S, Vanniasinkam T, Mohammed S, Vong R, Favaloro EJ. Semi-automated von Willebrand factor multimer assay for von Willebrand disease: further validation, benefits and limitations. Int J Lab Hematol 2019; 41 (06) 762-771
  CrossrefPubMedGoogle Scholar
• 52 Favaloro EJ. Classification of von Willebrand disease in the context of modern contemporary von Willebrand factor testing methodologies. Res Pract Thromb Haemost 2020; 4 (06) 952-957
  CrossrefPubMedGoogle Scholar
• 53 Favaloro EJ, Oliver S, Mohammed S, Vong R. Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies. Haemophilia 2020; 26 (03) 503-512
  CrossrefPubMedGoogle Scholar
• 54 Favaloro EJ, Mohammed S, Chapman K. et al. A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity. J Thromb Haemost 2021; 19 (02) 417-428
  CrossrefPubMedGoogle Scholar
• 55 Favaloro EJ, Thachil J. Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation. Clin Chem Lab Med 2020; 58 (08) 1191-1199
  CrossrefPubMedGoogle Scholar
• 56 Lippi G, Sanchis-Gomar F, Favaloro EJ, Lavie CJ, Henry BM. Coronavirus disease 2019-associated coagulopathy. Mayo Clin Proc 2021; 96 (01) 203-217
  CrossrefPubMedGoogle Scholar
• 57 Levi M, Thachil J. Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both. Semin Thromb Hemost 2020; 46 (07) 781-784
  Article in Thieme ConnectPubMedGoogle Scholar
• 58 Thachil J, Srivastava A. SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: Is it pulmonary thrombosis or pulmonary embolism?. Semin Thromb Hemost 2020; 46 (07) 777-780
  Article in Thieme ConnectPubMedGoogle Scholar
• 59 Schulman S. Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism. Semin Thromb Hemost 2020; 46 (07) 772-776
  Article in Thieme ConnectPubMedGoogle Scholar
• 60 Annane D, Heming N, Grimaldi-Bensouda L. et al; Garches COVID 19 Collaborative Group. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. EClinicalMedicine 2020; 28: 100590
  CrossrefPubMedGoogle Scholar
• 61 Laurence J, Mulvey JJ, Seshadri M. et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol 2020; 219: 108555
  CrossrefPubMedGoogle Scholar
• 62 Giudice V, Pagliano P, Vatrella A. et al. Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study. Front Pharmacol 2020; 11: 857
  CrossrefPubMedGoogle Scholar